SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.11-2.6%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (5183)12/20/2001 2:51:46 PM
From: Ian@SI  Read Replies (1) of 52153
 
Peter,

It seems even more sinister than that. On the surface, it may just be a ploy to keep the profits from an expanding market for the drugs out of CEPH's bottom line and put them into the joint venture. No incremental R&D, no FDA risk, just Marketing and Sales risks. If I were a CEPH shareholder, I'd certainly want to look at the prospectus with a view to ensuring that shareholder's assets aren't being unfairly disposed of.

FWIW,
Ian
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News